日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

(Giga)TIME for the era of AI: virtual multiplex immunofluorescence from routine H&E for large populations

面向人工智能时代的(Giga)TIME:基于常规H&E染色的大规模人群虚拟多重免疫荧光检测

Yang, Shao-Ping; Yu, Dihua

Retraction Note: Circular RNA circDCUN1D4 suppresses hepatocellular carcinoma development via targeting the miR-590-5p/ TIMP3 axis

撤稿声明:环状RNA circDCUN1D4通过靶向miR-590-5p/TIMP3轴抑制肝细胞癌的发生发展。

Li, Hongyu; Su, Bing; Jiang, Yan; Zhang, Boyang; Du, Rulong; Song, Can; Hou, Bin; Xu, Kun; Wu, Lida; Gu, Yuchun

TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy.

TIMELESS 通过抑制转铁蛋白介导的铁死亡促进 LUAD 生长,并重编程肿瘤微环境以对抗抗 PD-1 免疫疗法。

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study

Ublituximab治疗多发性硬化症五年:ULTIMATE I 和 II 开放标签扩展研究

Cree, Bruce A C; Fox, Edward; Hartung, Hans-Peter; Alvarez, Enrique; Qian, Peiqing; Wray, Sibyl; Robertson, Derrick; Selmaj, Krzysztof; Wynn, Daniel; Mok, Koby; Rowland, Chris; Bodhinathan, Karthik; Sportelli, Peter; Miskin, Hari P; Steinman, Lawrence

Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414

关于在未接受过生物制剂DMARD治疗的活动性银屑病关节炎患者中应用Bimekizumab治疗的更正:来自III期随机、安慰剂对照、活性参考BE OPTIMAL研究的52周疗效和安全性结果 Ann Rheum Dis. 2023;82:1404-1414

Ritchlin, Christopher T; Coates, Laura C; McInnes, Iain B; Mease, Philip J; Merola, Joseph F; Tanaka, Yoshiya; Asahina, Akihiko; Gossec, Laure; Gottlieb, Alice B; Warren, Richard B; Ink, Barbara; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Landewé, Robert B M

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy

NEO-STIM推进个性化新抗原特异性过继性T细胞疗法

Lenkala, Divya; Kohler, Jessica; McCarthy, Brian; Nelson, Michael; Bakker, Noor A M; de Boer, Renate; Jackson, Emily K; Sheen, Joong Hyuk F; Hannes, Susan; Esaulova, Ekaterina; Stewart, Kai; Gottstein, Claudia; Attanasio, John; Brown, Flavian D; Hymson, Sebastian; Meda, Shirisha; van Zon, Maaike; Scheij, Saskia; Voogd, Rhianne; Raud, Brenda; Xu, Ziyan; Borgers, Jessica S W; Rohaan, Maartje W; Balogh, Kristen N; Poran, Asaf; Rooney, Michael; Dong, Jesse Z; Srouji, John R; Juneja, Vikram R; Arieta, Christina M; Nijenhuis, Cynthia M; Nuijen, Bastiaan; DeMario, Mark; Manson, Kelledy; Schumacher, Ton N M; Gaynor, Richard B; Haanen, John B; van den Berg, Joost H; van Buuren, Marit M

STIM1-Mitofusin2 interactions tether mitochondria and melanosome contacts that promote melanosome maturation.

STIM1-Mitofusin2 相互作用将线粒体和黑素体连接起来,促进黑素体成熟。

Shiiba Isshin, Ishikawa Yuto, Oshio Hijiri, Ito Naoki, Yamaguchi Fuya, Nagashima Shun, Ando Hideya, Umezawa Keitaro, Miura Yuri, Araiso Yuhei, Nakamura Koki, Hirabayashi Yusuke, Inatome Ryoko, Yanagi Shigeru

Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial

阿贝拉西单抗与利伐沙班治疗老年房颤患者:AZALEA-TIMI 71 2b 期试验的预设分析

Al Said, Samer; Patel, Siddharth M; Giugliano, Robert P; Morrow, David A; Goodrich, Erica L; Murphy, Sabina A; Hug, Bruce; Parkar, Sanobar; Chen, Shih-Ann; Goodman, Shaun G; Joung, Boyoung; Kiss, Robert G; Wojakowski, Wojciech; Weitz, Jeffrey I; Bloomfield, Dan; Sabatine, Marc S; Ruff, Christian T

Targeting the SOX9/TIMP1 Axis with iRGD-Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer.

利用 iRGD 偶联纳米平台靶向 SOX9/TIMP1 轴可增强树突状细胞功能和光动力免疫疗法在胃癌中的疗效。

Unraveling TIME: CD8+ T cell- and CXCL11-driven endocrine resistance in breast cancer

揭开TIME的秘密:CD8+ T细胞和CXCL11驱动的乳腺癌内分泌耐药性

Kong, Tim; Ma, Cynthia X